Glaukos is pleased to announce the new addition to the iStent family – iStent infinite® is now available.
An Australian study found that visual field testing for glaucoma can be quite stressful and physically uncomfortable, but small changes like allowing breaks and improving patient education could make the experience better.
The Snow Medical Research Foundation and the University of Sydney have launched the AU$50 million Snow Vision Accelerator programme to develop innovative therapies for glaucoma.
Researchers at the University of New South Wales (UNSW) are conducting a project to find out about peoples’ priorities when choosing between different types of surgery.
A study from China suggests that high levels of 'good' cholesterol (HDL) may increase the risk of glaucoma, while higher levels of 'bad' cholesterol (LDL) and triglycerides could lower the risk, challenging traditional views on cholesterol and eye health.
The latest research proves that stress, anxiety, and depression can worsen glaucoma, harming a patient's mental health and impacting their quality of life...
PolyActiva’s proprietary implant is designed to address the long-standing challenge of poor patient adherence with traditional eye drop therapy...
A detailed analysis of the LiGHT Trial confirms that selective laser trabeculoplasty (SLT) slows glaucoma progression by 29% compared to eye drops. The findings, supported highlight SLT’s ability to reduce vision loss and the need for surgery, prompting its inclusion in international glaucoma treatment guidelines.
A/Prof Owen Siggs, recipient of the Glaucoma Australia ‘Quinlivan’ Research Grant in 2022 is now 18 months into his research into the Genomic Risk Stratification to improve glaucoma suspect triage in rural primary care.